Overview

Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia

Status:
Terminated
Trial end date:
2010-05-01
Target enrollment:
0
Participant gender:
All
Summary
Schizophrenia patients treated with clozapine have a high prevalence of obesity-related metabolic syndrome. The condition is often poorly treated and may lead to the emergence of coronary heart disease and type 2 diabetes. The study will investigate whether structured treatment provided at the site of the outpatient psychiatric clinic of metabolic syndrome in this population will decrease the severity of metabolic syndrome as compared with usual care received by these patients in the community.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Northwell Health
Treatments:
Clozapine
Fenofibrate
Irbesartan
Metformin
Orlistat
Pravastatin
Criteria
Inclusion Criteria:

- patients with schizophrenia treated with clozapine; age 19-79

Exclusion Criteria:

- pregnant women, personal history of/or comorbid eating disorders